Aura Biosciences (AURA) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Solid Biosciences (SLDB) has outperformed Aura Biosciences (AURA) over the past year, gaining 33.0% versus a gain of 26.3%. Over five years, AURA leads with a -69.6% price change compared with -77.8% for SLDB. Aura Biosciences is the larger company by market cap ($715.0 million vs $697.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | SLDB |
|---|---|---|
| Share price | $6.87 | $6.25 |
| Market cap | $714.99M | $697.57M |
| 1-day change | -1.58% | -2.95% |
| YTD return | +26.06% | +10.82% |
| 1-year return | +26.29% | +32.98% |
| 5-year return | -69.63% | -77.78% |
| EPS (TTM) | $-1.59 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-106.19M | $-174.32M |
| 52-week high | $9.54 | $11.45 |
| 52-week low | $4.73 | $4.65 |
| Distance from 52-week high | -27.95% | -45.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +141.63% | +199.36% |
| Average volume | 847.22K | 1.30M |
| Shares outstanding | 104.07M | 111.61M |
| Employees | 113 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
AURA vs SLDB FAQ
Which is bigger, Aura Biosciences or Solid Biosciences?
Aura Biosciences (AURA) is larger, with a market capitalization of $714.99M compared with $697.57M for Solid Biosciences (SLDB).
Which stock has performed better over the past year, AURA or SLDB?
SLDB returned +32.98% over the past 12 months, compared with +26.29% for AURA (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.